# Part E—General Provisions Relating to Drugs and Devices

Part E—General Provisions Relating to Drugs and Devices is a U.S. Code division of [Subchapter V—Drugs and Devices](https://ontology.bommaritollc.com/id/01a0f06c-cb96-7040-b454-c8f18e0e95cb); in force.

IRI: <https://ontology.bommaritollc.com/id/01a0f06c-cb9b-72d3-b67d-4d99ebbaa239>

Within: [Title 21—Food and Drugs](https://ontology.bommaritollc.com/id/01a0f06c-cb65-7672-8fda-c39517ff08c0) › [Chapter 9—Federal Food, Drug, and Cosmetic Act](https://ontology.bommaritollc.com/id/01a0f06c-cb91-72e0-858b-060e8c845f23) › [Subchapter V—Drugs and Devices](https://ontology.bommaritollc.com/id/01a0f06c-cb96-7040-b454-c8f18e0e95cb)

Type: [schema:Legislation](https://schema.org/Legislation)

- `adms:identifier`: [usc-division 21 U.S.C. Chapter 9, Subchapter V, Part E](https://ontology.bommaritollc.com/id/01a0f06c-cb9b-72d3-b67d-4da3c8e3e909)
- `prov:wasDerivedFrom`:
  - [evidence from https://www.govinfo.gov/app/details/USCODE-2024-title21](https://ontology.bommaritollc.com/id/01a0f06c-cb9b-72d3-b67d-4d980bee5a20)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f06c-d06b-73f9-ae9d-805b5d6fdc39)
- `schema:isPartOf`: [Subchapter V—Drugs and Devices](https://ontology.bommaritollc.com/id/01a0f06c-cb96-7040-b454-c8f18e0e95cb)
- `schema:legislationIdentifier`: 21 U.S.C. Chapter 9, Subchapter V, Part E
- `schema:legislationJurisdiction`: [United States](https://ontology.bommaritollc.com/id/01a0ed8e-f797-7004-b7f5-bec2695977c0)
- `schema:legislationLegalForce`: [schema:InForce](https://schema.org/InForce)
- `schema:legislationType`: [U.S. Code division](https://ontology.bommaritollc.com/vocab/leg/uscDivision)
- `skos:prefLabel`: Part E—General Provisions Relating to Drugs and Devices

## Elsewhere

- [Source](https://www.govinfo.gov/app/details/USCODE-2024-title21) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/) (www.govinfo.gov)

## Pointing here

- Parts (21; `schema:isPartOf`):
  - [21 U.S.C. 360bbb Expanded access to unapproved therapies and diagnostics](https://ontology.bommaritollc.com/id/01a0f06c-cd38-7075-88aa-4ae03ffd903d)
  - [21 U.S.C. 360bbb-0 Expanded access policy required for investigational drugs](https://ontology.bommaritollc.com/id/01a0f06c-cd39-74a5-b7bd-94789cf233c0)
  - [21 U.S.C. 360bbb-0a Investigational drugs for use by eligible patients](https://ontology.bommaritollc.com/id/01a0f06c-cd3a-70c9-89b0-2b4237b8a48f)
  - [21 U.S.C. 360bbb-1 Dispute resolution](https://ontology.bommaritollc.com/id/01a0f06c-cd3c-718c-b848-ae6c8764bfcf)
  - [21 U.S.C. 360bbb-2 Classification of products](https://ontology.bommaritollc.com/id/01a0f06c-cd3d-7752-9935-77e1c7b3b3df)
  - [21 U.S.C. 360bbb-3 Authorization for medical products for use in emergencies](https://ontology.bommaritollc.com/id/01a0f06c-cd3e-761c-8012-5367ede47b18)
  - [21 U.S.C. 360bbb-3a Emergency use of medical products](https://ontology.bommaritollc.com/id/01a0f06c-cd3f-71d5-9114-5c098a8367f2)
  - [21 U.S.C. 360bbb-3b Products held for emergency use](https://ontology.bommaritollc.com/id/01a0f06c-cd41-74b2-9306-be4213459872)
  - [21 U.S.C. 360bbb-3c Expedited development and review of medical products for emergency uses](https://ontology.bommaritollc.com/id/01a0f06c-cd42-7180-a20f-e2d054a3a620)
  - [21 U.S.C. 360bbb-4 Countermeasure development, review, and technical assistance](https://ontology.bommaritollc.com/id/01a0f06c-cd43-77c1-8452-5697f21f29ad)
  - [21 U.S.C. 360bbb-4a Priority review to encourage treatments for agents that present national security threats](https://ontology.bommaritollc.com/id/01a0f06c-cd45-71a8-a22e-0ede89b0ce4c)
  - [21 U.S.C. 360bbb-4b Medical countermeasure master files](https://ontology.bommaritollc.com/id/01a0f06c-cd46-7047-94e5-2dd72ff37f2d)
  - [21 U.S.C. 360bbb-5 Critical Path Public-Private Partnerships](https://ontology.bommaritollc.com/id/01a0f06c-cd48-7222-a8aa-c5cbdc8ff75f)
  - [21 U.S.C. 360bbb-5a Emerging technology program](https://ontology.bommaritollc.com/id/01a0f06c-cd49-7776-a7f9-319f4c749d15)
  - [21 U.S.C. 360bbb-6 Risk communication](https://ontology.bommaritollc.com/id/01a0f06c-cd4a-7387-a905-491b4710492b)
  - [21 U.S.C. 360bbb-7 Notification](https://ontology.bommaritollc.com/id/01a0f06c-cd4b-7742-865e-cf73e9172ca1)
  - [21 U.S.C. 360bbb-8 Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments](https://ontology.bommaritollc.com/id/01a0f06c-cd4c-73a0-842e-b15ab7e34ffb)
  - [21 U.S.C. 360bbb-8a Optimizing global clinical trials](https://ontology.bommaritollc.com/id/01a0f06c-cd4d-74bc-a4c3-68608e35ff06)
  - [21 U.S.C. 360bbb-8b Use of clinical investigation data from outside the United States](https://ontology.bommaritollc.com/id/01a0f06c-cd4f-73c4-ba75-25e0bc3bc948)
  - [21 U.S.C. 360bbb-8c Patient participation in medical product discussion](https://ontology.bommaritollc.com/id/01a0f06c-cd50-70b6-ad25-5e623cf1144a)
  - [21 U.S.C. 360bbb-8d Notification, nondistribution, and recall of controlled substances](https://ontology.bommaritollc.com/id/01a0f06c-cd51-70d2-81c2-d5e00eceaa51)

---
Also as: [Turtle](https://ontology.bommaritollc.com/id/01a0f06c-cb9b-72d3-b67d-4d99ebbaa239.ttl), [JSON-LD](https://ontology.bommaritollc.com/id/01a0f06c-cb9b-72d3-b67d-4d99ebbaa239.jsonld), [N-Triples](https://ontology.bommaritollc.com/id/01a0f06c-cb9b-72d3-b67d-4d99ebbaa239.nt), [HTML](https://ontology.bommaritollc.com/id/01a0f06c-cb9b-72d3-b67d-4d99ebbaa239)
Cite as: Part E—General Provisions Relating to Drugs and Devices. bc-ontology, release 0.1.0-rc38, 2026-10-21. https://ontology.bommaritollc.com/id/01a0f06c-cb9b-72d3-b67d-4d99ebbaa239
Release 0.1.0-rc38, graph hash 05350a11cf9d0c42fba51e92b877115781ab65cb92afcd6b172ff9f8f4abf0bd.
